These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25681866)

  • 1. Molecular imaging of levodopa-induced dyskinesias.
    Niccolini F; Rocchi L; Politis M
    Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
    J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
    Pagano G; Yousaf T; Politis M
    Curr Neurol Neurosci Rep; 2017 Oct; 17(11):90. PubMed ID: 28975571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
    Niccolini F; Loane C; Politis M
    Eur J Neurol; 2014 May; 21(5):694-9, e39-43. PubMed ID: 24471508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.
    Brusa L; Orlacchio A; Stefani A; Galati S; Pierantozzi M; Iani C; Mercuri NB
    Funct Neurol; 2013; 28(2):101-5. PubMed ID: 24125559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Levodopa for Parkinson's disease: What have we learned?].
    Juri C C; Chaná C P
    Rev Med Chil; 2006 Jul; 134(7):893-901. PubMed ID: 17130974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies.
    Pagano G; Niccolini F; Politis M
    J Neural Transm (Vienna); 2018 Aug; 125(8):1217-1223. PubMed ID: 29264660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
    Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
    Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA; Williams DR
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
    Smith R; Wu K; Hart T; Loane C; Brooks DJ; Björklund A; Odin P; Piccini P; Politis M
    Neurobiol Aging; 2015 Apr; 36(4):1736-1742. PubMed ID: 25649022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing levodopa-induced dyskinesias.
    Olanow CW; Obeso JA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.